Ultragenyx Pharmaceutical Inc.
No trades
No trades
Fundamentals and stats
Top segments and regional performance
Last year, the company generated 673.00 M USD, the most of which — 673.00 M USD — came from its top-performing segment, Novel Products, compared to 560.23 M USD the previous year. The greatest contribution came from North America, which accounted for 377.00 M USD last year, with 340.46 M USD the year before.
By source
By country